Neumora Financial Statements From 2010 to 2026

NMRA Stock   3.20  0.05  1.54%   
Neumora Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neumora Therapeutics' valuation are provided below:
Market Capitalization
552.3 M
Earnings Share
(1.47)
We have found one hundred twenty available fundamental ratios for Neumora Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Neumora Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Neumora Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neumora Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 557.9 K, Selling General Administrative of 37.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.56. Neumora financial statements analysis is a perfect complement when working with Neumora Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Neumora Stock
Check out the analysis of Neumora Therapeutics Correlation against competitors.
For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.

Neumora Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities15.8 M28.4 M7.7 M
Slightly volatile
Total Current Liabilities20.4 M34.4 M9.8 M
Slightly volatile
Common Stock Shares Outstanding169.8 M183.3 M155.7 M
Slightly volatile
Total Liabilities25.6 M26.9 M119.4 M
Slightly volatile
Short and Long Term Debt TotalM2.1 M2.6 M
Slightly volatile
Current Deferred Revenue15.8 M24.4 M10.3 M
Slightly volatile
Non Currrent Assets OtherM1.1 M1.2 M
Slightly volatile
Other Assets5.1 M4.7 MM
Slightly volatile
Cash And Short Term Investments381.6 M353.7 M258.2 M
Slightly volatile
Net Receivables606.6 K1.1 M371.3 K
Slightly volatile
Liabilities And Stockholders Equity410.7 M364.5 M271.8 M
Slightly volatile
Other Current Assets11.6 M7.4 M5.2 M
Slightly volatile
Other Stockholder Equity1.5 B1.4 B317.8 M
Slightly volatile
Short Term Debt2.3 M2.1 M1.3 M
Slightly volatile
Common Stock11.2 K18.4 K12.4 K
Very volatile
Property Plant Equipment6.8 M12.2 M5.8 M
Slightly volatile
Other Liabilities557.7 K722.2 K458.6 K
Slightly volatile
Inventory70 K45 K103.8 K
Slightly volatile
Deferred Long Term Liabilities2.6 M3.3 M2.2 M
Slightly volatile
Non Current Liabilities Other18.8 K19.8 K322.1 K
Slightly volatile

Neumora Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization557.9 K725.6 K286.4 K
Slightly volatile
Selling General Administrative37.9 M71.9 M21.5 M
Slightly volatile
Other Operating Expenses202.5 M303 M140.1 M
Slightly volatile
Research Development164.6 M231.1 M118.5 M
Slightly volatile
Total Operating Expenses202.3 M303 M140 M
Slightly volatile
Reconciled Depreciation557.9 K725.6 K286.4 K
Slightly volatile
Cost Of Revenue571.1 K601.2 K1.4 M
Slightly volatile
Selling And Marketing Expenses534.4 K601.2 K656.2 K
Slightly volatile

Neumora Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation484.2 K725.6 K282.1 K
Slightly volatile
Total Cash From Financing Activities18.5 M19.4 M190.1 M
Slightly volatile
Change To Netincome19.1 M20.1 M64.7 M
Slightly volatile
Stock Based Compensation48.3 M46 M10.7 M
Slightly volatile
Issuance Of Capital Stock11.7 M12.3 M152.4 M
Slightly volatile
End Period Cash Flow218 M129 M213.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.190.28.1947
Slightly volatile
Payables Turnover1.581.781.9466
Slightly volatile
Cash Per Share1.791.741.6092
Slightly volatile
Days Payables Outstanding147166181
Slightly volatile
Income Quality0.460.680.3967
Slightly volatile
Net Debt To EBITDA0.580.611.7074
Slightly volatile
Current Ratio18.5812.0818.9413
Slightly volatile
Capex Per Share8.0E-48.0E-40.0062
Slightly volatile
Interest Debt Per Share0.02030.01050.0172
Slightly volatile
Debt To Assets0.01130.00670.0102
Very volatile
Days Of Payables Outstanding147166181
Slightly volatile
Ebt Per Ebit0.830.92461.0137
Slightly volatile
Quick Ratio18.5812.0818.9413
Slightly volatile
Net Income Per E B T1.11.151.0157
Slightly volatile
Cash Ratio5.25.4716.6731
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0483
Pretty Stable
Debt Ratio0.01130.00670.0102
Very volatile

Neumora Fundamental Market Drivers

Neumora Upcoming Events

7th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Neumora Therapeutics Financial Statements

Neumora Therapeutics stakeholders use historical fundamental indicators, such as Neumora Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Neumora Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neumora Therapeutics' assets and liabilities are reflected in the revenues and expenses on Neumora Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neumora Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue24.4 M15.8 M
Cost Of Revenue601.2 K571.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neumora Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics Stock:
Check out the analysis of Neumora Therapeutics Correlation against competitors.
For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics. Anticipated expansion of Neumora directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Neumora Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.47)
Return On Assets
(0.57)
Return On Equity
(1.04)
Understanding Neumora Therapeutics requires distinguishing between market price and book value, where the latter reflects Neumora's accounting equity. The concept of intrinsic value - what Neumora Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Neumora Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Neumora Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neumora Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neumora Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.